174080-08-1

Upstream product

• 140-88-5 ethyl acrylate 
• 79-37-8 oxalyl dichloride 
• 190321-74-5 ethyl 4-(hydroxymethyl)cyclohexane-1-carboxylate 
• 13380-84-2 4-(hydroxymethyl)cyclohexane-1-carboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 4009-98-7 (methoxymethyl)triphenylphosphonium chloride 

Downstream Products

• 115883-99-3 4-((2R,4aR,6S,8aS)-6-Pentyl-hexahydro-benzo[1,3]dioxin-2-yl)-cyclohexanecarboxylic acid ethyl ester 
• 1443021-36-0 C₃₄H₄₄N₂O₇ 
• 15177-66-9 trans-1,4-cyclohexanedicarboxylic acid monoethyl ester 

Relevant academic research and scientific papers

Synthesis of 1,4-Cyclohexanedimethanol, 1,4-Cyclohexanedicarboxylic Acid and 1,2-Cyclohexanedicarboxylates from Formaldehyde, Crotonaldehyde and Acrylate/Fumarate

Valuable polyester monomers and plasticizers—1,4-cyclohexanedimethanol (CHDM), 1,4-cyclohexanedicarboxylic acid (CHDA), and 1,2-cyclohexanedicarboxylates—have been prepared by a new strategy. The synthetic processes involve a proline-catalyzed formal [3+1+2] cycloaddition of formaldehyde, crotonaldehyde, and acrylate (or fumarate). CHDM is produced after a subsequent hydrogenation step over a commercially available Cu/Zn/Al catalyst and a one-pot hydrogenation/oxidation/hydrolysis process yields CHDA, whereas 1,2-cyclohexanedicarboxylate is obtained by a Pd/C-catalyzed tandem decarbonylation/hydrogenation step.

AMINOPYRIMIDINES AS SYK INHIBITORS

The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis and cancer.

HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula (I) wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES

The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

VIRAL POLYMERASE INHIBITORS

Compound of Formula I: wherein, R2, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase

Tolan derivatives, and liquid-crystalline medium

The invention relates to tolan derivatives of the formula I in which R1, R2, A, Z, L1, L2, L3, L4, L5, L6, Q, m and n are as defined herein.